JP2021500025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500025A5 JP2021500025A5 JP2020521880A JP2020521880A JP2021500025A5 JP 2021500025 A5 JP2021500025 A5 JP 2021500025A5 JP 2020521880 A JP2020521880 A JP 2020521880A JP 2020521880 A JP2020521880 A JP 2020521880A JP 2021500025 A5 JP2021500025 A5 JP 2021500025A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023151506A JP7645323B2 (ja) | 2017-10-20 | 2023-09-19 | Ｂ型肝炎感染の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575358P | 2017-10-20 | 2017-10-20 | |
| US62/575,358 | 2017-10-20 | ||
| PCT/US2018/056801 WO2019079781A2 (en) | 2017-10-20 | 2018-10-19 | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151506A Division JP7645323B2 (ja) | 2017-10-20 | 2023-09-19 | Ｂ型肝炎感染の治療方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021500025A JP2021500025A (ja) | 2021-01-07 |
| JP2021500025A5 true JP2021500025A5 (https=) | 2023-07-21 |
| JPWO2019079781A5 JPWO2019079781A5 (https=) | 2023-07-21 |
| JP7353276B2 JP7353276B2 (ja) | 2023-09-29 |
Family
ID=66173915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521880A Active JP7353276B2 (ja) | 2017-10-20 | 2018-10-19 | Ｂ型肝炎感染の治療方法 |
| JP2023151506A Active JP7645323B2 (ja) | 2017-10-20 | 2023-09-19 | Ｂ型肝炎感染の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151506A Active JP7645323B2 (ja) | 2017-10-20 | 2023-09-19 | Ｂ型肝炎感染の治療方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10799524B2 (https=) |
| EP (2) | EP3684377B1 (https=) |
| JP (2) | JP7353276B2 (https=) |
| KR (1) | KR102783206B1 (https=) |
| CN (2) | CN111372593B (https=) |
| AU (1) | AU2018351649B2 (https=) |
| BR (1) | BR112020007476A2 (https=) |
| CA (1) | CA3078960A1 (https=) |
| CL (1) | CL2020001061A1 (https=) |
| CO (1) | CO2020005135A2 (https=) |
| CR (1) | CR20200163A (https=) |
| DK (1) | DK3684377T3 (https=) |
| ES (1) | ES2936863T3 (https=) |
| FI (1) | FI3684377T3 (https=) |
| HR (1) | HRP20230023T1 (https=) |
| HU (1) | HUE061122T2 (https=) |
| IL (4) | IL274040B2 (https=) |
| LT (1) | LT3684377T (https=) |
| MA (1) | MA50264B1 (https=) |
| MX (1) | MX2020004060A (https=) |
| MY (1) | MY201698A (https=) |
| PE (1) | PE20220561A1 (https=) |
| PH (1) | PH12020550591A1 (https=) |
| PL (1) | PL3684377T3 (https=) |
| PT (1) | PT3684377T (https=) |
| RS (1) | RS64001B1 (https=) |
| SG (1) | SG11202003488WA (https=) |
| SI (1) | SI3684377T1 (https=) |
| UA (1) | UA128786C2 (https=) |
| WO (1) | WO2019079781A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3684377T1 (sl) | 2017-10-20 | 2023-05-31 | Dicerna Pharmaceuticals, Inc. | Postopki zdravljenja okužbe s hepatitisom B |
| EP4512407A3 (en) | 2018-07-13 | 2025-09-24 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating rtel1 expression |
| WO2021067744A1 (en) * | 2019-10-02 | 2021-04-08 | Dicerna Pharmaceuticals, Inc. | Chemical modifications of small interfering rna with minimal fluorine content |
| JP2023506954A (ja) * | 2019-12-19 | 2023-02-20 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用 |
| CN114828852A (zh) * | 2019-12-24 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合 |
| EP4081639A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| CA3187388A1 (en) * | 2020-07-27 | 2022-02-03 | Jin Hong | Hbv binding oligonucleotides and methods of use |
| CA3190794A1 (en) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Oligonucleotide treatment of hepatitis b patients |
| US20240124879A1 (en) * | 2020-12-18 | 2024-04-18 | Olix Pharmaceuticals, Inc. | Rnai agent for inhibiting hbv expression and use thereof |
| CN114853829A (zh) * | 2021-02-05 | 2022-08-05 | 上海拓界生物医药科技有限公司 | 一种核酸配体、其缀合物、制备方法及用途 |
| CN114621954B (zh) * | 2021-04-13 | 2023-01-31 | 厦门甘宝利生物医药有限公司 | 一种抑制乙型肝炎病毒基因表达的rna抑制剂及其应用 |
| WO2022223515A2 (en) | 2021-04-19 | 2022-10-27 | Novo Nordisk A/S | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| CA3234478A1 (en) | 2021-11-11 | 2023-05-19 | Souphalone LUANGSAY | Pharmaceutical combinations for treatment of hbv |
| JP2024541559A (ja) * | 2021-11-29 | 2024-11-08 | シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド | Ｂ型肝炎ウイルス（ｈｂｖ）タンパク質の発現を阻害するための組成物および方法 |
| EP4201947A1 (en) | 2021-12-22 | 2023-06-28 | F. Hoffmann-La Roche AG | Process for the backbone deprotection of oligonucleotides containing a terminal alkyl phosphonate group |
| WO2023116764A1 (zh) * | 2021-12-23 | 2023-06-29 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及其用途 |
| US20240309383A1 (en) * | 2023-02-24 | 2024-09-19 | Suzhou Sanegene Bio Inc. | Small interfering rna targeting hbv and uses thereof |
| WO2025199466A1 (en) | 2024-03-22 | 2025-09-25 | Purdue Research Foundation | Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use |
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127446A1 (en) | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20030176372A1 (en) | 2001-05-04 | 2003-09-18 | Technologie Integrale Ltd | Anti-virus agent |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| JP2005508196A (ja) | 2001-11-07 | 2005-03-31 | アプレラ コーポレイション | 核酸分析の汎用ヌクレオチド |
| EP2305812A3 (en) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2008016391A2 (en) | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
| EP2799547B1 (en) * | 2006-11-08 | 2016-12-21 | Veritas Bio, LLC | In Vivo Delivery of RNA to a Target Cell |
| EP2164965B1 (en) | 2007-05-29 | 2013-09-11 | University Of The Witwatersrand, Johannesburg | A primary micro rna expression cassette |
| JP2012504389A (ja) | 2008-09-22 | 2012-02-23 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法 |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| KR20120095397A (ko) * | 2009-10-16 | 2012-08-28 | 글락소 그룹 리미티드 | Ｈｂｖ 안티센스 억제제 |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| PH12019502377A1 (en) * | 2011-04-21 | 2022-11-14 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
| HRP20181564T1 (hr) * | 2011-06-30 | 2018-11-30 | Arrowhead Pharmaceuticals, Inc. | Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b |
| JP2015501155A (ja) | 2011-10-25 | 2015-01-15 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｇｃｃｒ発現のアンチセンス調整 |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| CN105189541A (zh) * | 2012-12-14 | 2015-12-23 | 戴瑟纳制药公司 | 用于通过双链rna特异性抑制ckap5的方法和组合物 |
| CN103333890B (zh) | 2012-12-21 | 2015-04-15 | 厦门成坤生物技术有限公司 | 治疗乙型病毒性肝炎的rna干扰制剂 |
| JP6306750B2 (ja) | 2014-03-07 | 2018-04-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン |
| GB201408623D0 (en) * | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| JP2017522046A (ja) | 2014-06-06 | 2017-08-10 | ソルスティス バイオロジクス，リミティッド | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
| CN104059916A (zh) | 2014-06-17 | 2014-09-24 | 湖北医药学院附属太和医院 | 乙肝病毒特异性的microRNA样siRNA序列及其用途 |
| WO2016030863A1 (en) * | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| TWI710633B (zh) * | 2014-11-10 | 2020-11-21 | 美商阿尼拉製藥公司 | Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法 |
| JP7105065B2 (ja) | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | リガンド修飾二本鎖核酸 |
| US10689647B2 (en) * | 2015-05-08 | 2020-06-23 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA |
| KR20180038465A (ko) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| KR20250065735A (ko) | 2016-03-14 | 2025-05-13 | 에프. 호프만-라 로슈 아게 | Pd-l1 발현의 감소를 위한 올리고뉴클레오티드 |
| WO2017211791A1 (en) | 2016-06-07 | 2017-12-14 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and a tlr7 agonist |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| HRP20231063T1 (hr) * | 2017-10-13 | 2023-12-22 | Novo Nordisk Health Care Ag | Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha |
| SI3684377T1 (sl) | 2017-10-20 | 2023-05-31 | Dicerna Pharmaceuticals, Inc. | Postopki zdravljenja okužbe s hepatitisom B |
| CA3190794A1 (en) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Oligonucleotide treatment of hepatitis b patients |
-
2018
- 2018-10-19 SI SI201830840T patent/SI3684377T1/sl unknown
- 2018-10-19 WO PCT/US2018/056801 patent/WO2019079781A2/en not_active Ceased
- 2018-10-19 CN CN201880068102.3A patent/CN111372593B/zh active Active
- 2018-10-19 KR KR1020207013967A patent/KR102783206B1/ko active Active
- 2018-10-19 MX MX2020004060A patent/MX2020004060A/es unknown
- 2018-10-19 IL IL274040A patent/IL274040B2/en unknown
- 2018-10-19 SG SG11202003488WA patent/SG11202003488WA/en unknown
- 2018-10-19 MY MYPI2020001980A patent/MY201698A/en unknown
- 2018-10-19 BR BR112020007476-4A patent/BR112020007476A2/pt unknown
- 2018-10-19 EP EP18868404.7A patent/EP3684377B1/en active Active
- 2018-10-19 RS RS20230047A patent/RS64001B1/sr unknown
- 2018-10-19 HR HRP20230023TT patent/HRP20230023T1/hr unknown
- 2018-10-19 MA MA50264A patent/MA50264B1/fr unknown
- 2018-10-19 ES ES18868404T patent/ES2936863T3/es active Active
- 2018-10-19 AU AU2018351649A patent/AU2018351649B2/en active Active
- 2018-10-19 CN CN202410274712.6A patent/CN118185936A/zh active Pending
- 2018-10-19 DK DK18868404.7T patent/DK3684377T3/da active
- 2018-10-19 CR CR20200163A patent/CR20200163A/es unknown
- 2018-10-19 CA CA3078960A patent/CA3078960A1/en active Pending
- 2018-10-19 LT LTEPPCT/US2018/056801T patent/LT3684377T/lt unknown
- 2018-10-19 PE PE2020000748A patent/PE20220561A1/es unknown
- 2018-10-19 FI FIEP18868404.7T patent/FI3684377T3/fi active
- 2018-10-19 UA UAA202002978A patent/UA128786C2/uk unknown
- 2018-10-19 PL PL18868404.7T patent/PL3684377T3/pl unknown
- 2018-10-19 IL IL312809A patent/IL312809B2/en unknown
- 2018-10-19 JP JP2020521880A patent/JP7353276B2/ja active Active
- 2018-10-19 EP EP22201680.0A patent/EP4197544A1/en active Pending
- 2018-10-19 IL IL319113A patent/IL319113A/en unknown
- 2018-10-19 IL IL282881A patent/IL282881B2/en unknown
- 2018-10-19 HU HUE18868404A patent/HUE061122T2/hu unknown
- 2018-10-19 PT PT188684047T patent/PT3684377T/pt unknown
-
2020
- 2020-02-14 US US16/790,986 patent/US10799524B2/en active Active
- 2020-04-17 PH PH12020550591A patent/PH12020550591A1/en unknown
- 2020-04-20 CL CL2020001061A patent/CL2020001061A1/es unknown
- 2020-04-24 CO CONC2020/0005135A patent/CO2020005135A2/es unknown
- 2020-07-07 US US16/922,007 patent/US11052104B2/en active Active
- 2020-07-07 US US16/922,033 patent/US11052105B2/en active Active
-
2021
- 2021-05-12 US US17/318,864 patent/US11273173B2/en active Active
-
2022
- 2022-02-02 US US17/649,781 patent/US12564601B2/en active Active
-
2023
- 2023-09-19 JP JP2023151506A patent/JP7645323B2/ja active Active